Trading Signals: NVAX Stock Price Prediction and Forecast (Tue. Apr. 1, 2003 - Tue. Jan. 26, 2021)(Novavax, Inc.)
| NVAX latest price $107.3200 (-6.36%) ($106.3000 - $116.3700) on Thu. Aug. 27, 2020. | |
| | Trend Analysis and Forecast | | | | Trend Pattern | Growing Downtrend | | Trend Narrative | Downtrend | | Average Daily Price Swing | $19.63 (13.71% one month average) | | Average Daily Percentage Swing | 7.72% (three month average) | | Weekly Trend Force | -2% (StdDev 7.72%) | | Daily Moving Force | -3.4% | | Rebound Strength | None(0%) | | Trend | -1.88% | | Trend Strength | -7.8% | | RSI | 31 | | Momentum | 1.8 | | Latest Price | $107.3200(-6.36%) | | Forecasted Low Price | 102.92(-4.1%) | | Forecasted High Price | 109.36(1.9%) | | Direction of Next Movement | Range(-3.8%) | | % Change Needed to Confirm Rebound | 13.6% ((121.88)) | | % Change Needed for Trend Reversal | 27% | | Hourly Trend | -0.5% [$111.97(-0.55), $114.12(-7.3)] | | Stocks Behave Similarly | Similar Stock List | | Complacency | 2 | | Intraday Reversal Probability | There's a high probability the price will reverse sharply to upside intraday or next day.. | | Daily Trend | NVAX declines -5.7% a day on average for past five trading days. | | Weekly Trend | NVAX declines -11.4% a week on average for past two weeks. | | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | | Correlated ETFs | Broad market will support NVAX advance at -0% a week (37% probability)
XBI(45%) IBB(38%) ARKG(35%) IPO(32%) ARKK(31%) | | Factors Impacting NVAX price | NVAX will decline at least -1.6% in a week (9% probabilities).
TBT(-13%) IYT(-9%) VXX(-8%) VIXM(-8%) HYXU(-5%) | | Trading Plan | Not Available | | | | | Valuation to SPY | -2.1 | | | | | Relative Volatility | 0.3 (options are faily valued) | | | | | Market Trend Strength | -3.6% (StdDev 7.72%) | | Hourly BBV | -4.2 () | | Intraday Trend | 0% | | | | | |
|
| Next Day Open Price | $108.22(0.84%) | | 1 - 5 Day Possible Target | $92.62(-13.7%) | | Resistance Level | $143.21 | | 5 Day Moving Average | $118.43(-9.38%) | | 10 Day Moving Average | $132.06(-18.73%) | | 20 Day Moving Average | $143.21(-25.06%) | | To recent high | -39.9% | | To recent low | 142.5% | | Market Cap | $6.569b | | | | Option Sentiment | | | | | | | Earning Release Date | Mon. Mar. 1, 2021 | | Analyst One Year Target Price | $227.60 ($105.00 - $290.00)
5 analysts (last updated on Wed. Aug. 5, 2020) | | % to Average Target Price | 112.08% | | % to Low Target Price | -2.16% | | % to High Target Price | 170.22% | | | | |
Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
JUL 7, 2020 Shares of NVAX surged more than 40% on the news ts has received $1.6 to develop and to deliver up to 100 million doses of the company’s late-stage Covid-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed program.
The vaccine, which focuses on boosting the body’s immune system to effectively combat a Covid-19 infection, is currently in phase 1 and phase 2 clinical trials in Australia, with preliminary results expected at the end of this month. |